Arthrosi Therapeutics doses first patient in replicate pivotal phase 3 REDUCE 1 trial of lead compound AR882: San Diego Wednesday, March 19, 2025, 11:00 Hrs [IST] Arthrosi Therape ...

Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, ...

However, given the likely contribution of higher comorbidities to poorer health outcomes among respondents, comorbid status may be confounded with gout flares and tophi in the analyses.

Background Although typically a late feature of gout, tophi may present early in the course of disease. The aim of this study was to identify factors associated with the presence of early ...

and dissolve tophi in gout and tophaceous gout patients, today announced the completion of enrollment for its pivotal global Phase 3 REDUCE 2 trial. "We would like to thank the gout community for ...

If you've ever been going about your day only to get hit with excruciating joint pain, it could be gout. While this type of ...

Gout can affect other joints. It may also cause “tophi” to develop (hard swellings around joints and the ears). Gout typically occurs in bouts or attacks, before settling with treatment and ...

Gout can affect other joints. It may also cause “tophi” to develop (hard swellings around joints and the ears). Gout typically occurs in bouts or attacks, before settling with treatment and becoming ...

They often strike at night and can last days to weeks if not treated. Gout medicines also prevent kidney stones and tophi (uric acid build-up below the skin, which can damage joints). The main ...